Aspirin therapy for colorectal cancer with PIK3CA mutation: Simply complex!

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4358-4361

  Fuchs, Charles S ^a   Ogino, Shuji ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; PROSTAGLANDIN SYNTHASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P85; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIK3CA PROTEIN, HUMAN; ROFECOXIB; SULFONE;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL LINE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; ENZYME INHIBITION; GENE MUTATION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; MICROENVIRONMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WILD TYPE; COLORECTAL NEOPLASMS; FEMALE; GENETICS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; COLORECTAL TUMOR; NOTE; TUMOR RECURRENCE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LACTONES; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; SULFONES;

EID: 84892882699     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.0080     Document Type: Article

References (49)

1. Arber N, Eagle CJ, Spicak J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895, 2006 (Pubitemid 44315981)
2. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899, 2003 (Pubitemid 36297997)
3. Baron JA, Sandler RS, Bresalier RS, et al: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682, 2006 (Pubitemid 44958508)
4. Benamouzig R, Deyra J, Martin A, et al: Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 125:328-336, 2003 (Pubitemid 36929412)
5. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884, 2006 (Pubitemid 44315980)
6. Logan RF, Grainge MJ, Shepherd VC, et al: Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29-38, 2008 (Pubitemid 350309319)
7. Sandler RS, Halabi S, Baron JA, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890, 2003 (Pubitemid 36297996)
8. Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750, 2010
9. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379:1591-1601, 2012
10. McCowan C, Munro AJ, Donnan PT, et al: Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49:1049-1057, 2013
11. Zell JA, Ziogas A, Bernstein L, et al: Nonsteroidal anti-inflammatory drugs: Effects on mortality after colorectal cancer diagnosis. Cancer 115:5662- 5671, 2009
12. Coghill AE, Newcomb PA, Campbell PT, et al: Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60:491-498, 2011
13. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-658, 2009
14. Bastiaannet E, Sampieri K, Dekkers OM, et al: Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 106:1564-1570, 2012
15. Chia WK, Ali R, Toh HC: Aspirin as adjuvant therapy for colorectal cancer: Reinterpreting paradigms. Nat Rev Clin Oncol 9:561-570, 2012
16. Ogino S, Kirkner GJ, Nosho K, et al: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14:8221-8227, 2008
17. Chan AT, Ogino S, Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142, 2007 (Pubitemid 47010839)
18. Bos CL, Kodach LL, van den Brink GR, et al: Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25:6447-6456, 2006 (Pubitemid 44607077)
19. Hanif R, Pittas A, Feng Y, et al: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52:237-245, 1996 (Pubitemid 26233752)
20. Thun MJ, Jacobs EJ, Patrono C: The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259-267, 2012
21. Dovizio M, Bruno A, Tacconelli S, et al: Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191:39-65, 2013
22. Liao X, Lochhead P, Nishihara R, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:1596-1606, 2012
23. Domingo E, Church DN, Sieber O, et al: Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 31:4297- 4305, 2013
24. Zhang J, Roberts TM, Shivdasani RA: Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 141:50-61, 2011
25. Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083, 2010
26. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009
27. Agarwal A, Das K, Lerner N, et al: The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 24:1021-1031, 2005 (Pubitemid 40313879)
28. Fang D, Hawke D, Zheng Y, et al: Phosphorylation of beta-catenin by AKT promotes betacatenin transcriptional activity. J Biol Chem 282: 11221-11229, 2007 (Pubitemid 47100795)
29. He XC, Yin T, Grindley JC, et al: PTENdeficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39:189-198, 2007 (Pubitemid 46184349)
30. Ng SS, Mahmoudi T, Danenberg E, et al: Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade. J Biol Chem 284:35308- 35313, 2009
31. Duronio V: The life of a cell: Apoptosis regulation by the PI3K/PKB pathway. Biochem J 415: 333-344, 2008
32. Khaleghpour K, Li Y, Banville D, et al: Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 25:241-248, 2004 (Pubitemid 38239808)
33. Lièvre A, Blons H, Laurent-Puig P: Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29:3033-3043, 2010
34. Liao X, Morikawa T, Lochhead P, et al: Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res 18:2257-2268, 2012
35. Velho S, Moutinho C, Cirnes L, et al: BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8:255, 2008
36. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004 (Pubitemid 38541907)
37. Karin M, Greten FR: NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759, 2005 (Pubitemid 41400849)
38. Li Q, Withoff S, Verma IM: Inflammationassociated cancer: NF-kappaB is the lynchpin. Trends Immunol 26:318-325, 2005
39. Hutti JE, Pfefferle AD, Russell SC, et al: Oncogenic PI3K mutations lead to NF-kappaBdependent cytokine expression following growth factor deprivation. Cancer Res 72:3260-3269, 2012
40. Williams JL, Ji P, Ouyang N, et al: NOdonating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis 29:390-397, 2008 (Pubitemid 351359679)
41. Loveridge CJ, MacDonald AD, Thoms HC, et al: The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene 27:2648-2655, 2008 (Pubitemid 351550873)
42. Funakoshi-Tago M, Shimizu T, Tago K, et al: Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol 76:662-671, 2008
43. Greenspan EJ, Madigan JP, Boardman LA, et al: Ibuprofen inhibits activation of nuclear {beta}- catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) 4:161-171, 2011
44. Din FV, Valanciute A, Houde VP, et al: Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142:1504.e3-1515.e3, 2012
45. Zhu J, Huang JW, Tseng PH, et al: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64:4309-4318, 2004 (Pubitemid 38802438)
46. Ogino S, Lochhead P, Giovannucci E, et al: Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: Power and promise of molecular pathological epidemiology. Oncogene [epub ahead of print on June 24, 2013]
47. Sheng H, Shao J, Washington MK, et al: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075- 18081, 2001
48. Tessner TG, Muhale F, Riehl TE, et al: Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114:1676-1685, 2004 (Pubitemid 40385559)
49. Yang N, Huang J, Greshock J, et al: Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One 3:e1758, 2008